Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01187186 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941

A Phase 1 study, sponsored by Astellas Pharma.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target

NCT01187186: Completed Phase 1 study, sponsored by Astellas Pharma.

NCT01187186 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01187186, a Phase 1 study, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) and safety following oral administration of ASP1941 in subjects with moderate hepatic impairment and in subjects with normal hepatic function based on the Child-Pugh Classification (CPC).

Interventions

  • DRUG ASP1941

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2010-05
Est. Completion 2010-08
Phase Phase 1
Astellas Pharma

165 total trials

What the finished NCT01187186 record still lists

NCT01187186 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).

The record links to 0 conditions, and to 1 intervention - of which ASP1941 is the first listed.

NCT01187186 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01187186 about?

NCT01187186 is a clinical study titled "A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941". The purpose of this study is to evaluate the pharmacokinetics (PK) and safety following oral administration of ASP1941 in subjects with moderate hepatic impairment and in subjects with normal hepatic function based on the Child-Pugh Classification (CPC).

What is the current status of trial NCT01187186?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-05. Estimated completion is 2010-08.

What interventions are being tested in trial NCT01187186?

The interventions under investigation include: ASP1941 (DRUG).

Who is sponsoring clinical trial NCT01187186?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01187186's enrollment target sits among peer trials

16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01187186, the US trial registry maintained by the National Library of Medicine. NCT01187186 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.